{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2%2FNeu-positive+Breast+Cancer&page=2", "query": { "condition": "HER2/Neu-positive Breast Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2%2FNeu-positive+Breast+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T16:10:13.912Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02236572", "title": "Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 17, "start_date": "2014-11-29", "completion_date": "2021-03-01", "has_results": true, "last_update_posted_date": "2022-02-01", "last_synced_at": "2026-06-25T16:10:13.912Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02236572" }, { "nct_id": "NCT02049957", "title": "Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 118, "start_date": "2014-02-13", "completion_date": "2018-06-29", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-06-25T16:10:13.912Z", "location_count": 30, "location_summary": "Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02049957" }, { "nct_id": "NCT07310420", "title": "A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "ZOLADEX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TerSera Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 88, "start_date": "2026-06-30", "completion_date": "2027-03-30", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-25T16:10:13.912Z", "location_count": 11, "location_summary": "Hot Springs, Arkansas • Washington D.C., District of Columbia • Ocoee, Florida + 8 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Lisle", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07310420" }, { "nct_id": "NCT02871791", "title": "Palbociclib With Everolimus + Exemestane In BC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Hormone Receptor (HR)-Positive Breast Cancer" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2016-08-24", "completion_date": "2021-09", "has_results": true, "last_update_posted_date": "2022-08-29", "last_synced_at": "2026-06-25T16:10:13.912Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02871791" }, { "nct_id": "NCT07191717", "title": "Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Invasive Breast Carcinoma", "Localized Estrogen Receptor-Positive Breast Carcinoma", "Localized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiologic Imaging Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2026-04-30", "completion_date": "2031-04-30", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-06-25T16:10:13.912Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07191717" }, { "nct_id": "NCT01674140", "title": "S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "anastrozole", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "exemestane", "type": "DRUG" }, { "name": "goserelin acetate", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "leuprolide acetate", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1939, "start_date": "2013-09-12", "completion_date": "2030-01", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-06-25T16:10:13.912Z", "location_count": 1455, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 887 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01674140" }, { "nct_id": "NCT04460911", "title": "Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2019-10-19", "completion_date": "2022-04-01", "has_results": true, "last_update_posted_date": "2024-01-11", "last_synced_at": "2026-06-25T16:10:13.912Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04460911" }, { "nct_id": "NCT01754519", "title": "Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ductal Breast Carcinoma In Situ", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "HER2/Neu Negative", "Invasive Cribriform Breast Carcinoma", "Invasive Ductal Carcinoma, Not Otherwise Specified", "Lobular Breast Carcinoma In Situ", "Mucinous Breast Carcinoma", "Papillary Breast Carcinoma", "Progesterone Receptor Positive", "Stage I Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIC Breast Cancer", "Tubular Breast Carcinoma" ], "interventions": [ { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "FEMALE", "summary": "50 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2013-05", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-07-07", "last_synced_at": "2026-06-25T16:10:13.912Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01754519" }, { "nct_id": "NCT04585750", "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Advanced Malignant Neoplasm", "Metastatic Cancer", "Metastatic Solid Tumor", "Lung Cancer", "Ovarian Cancer", "Endometrial Cancer", "Prostate Cancer", "Colorectal Cancer", "Breast Cancer", "Other Cancer", "Locally Advanced", "Head and Neck Cancer", "Gall Bladder Cancer", "Small Cell Lung Cancer", "Small Cell Lung Cancer ( SCLC )", "Small Cell Lung Carcinoma", "NSCLC", "NSCLC (Non-small Cell Lung Cancer)", "SCLC", "Non-Small Cell Lung Carcinoma", "Triple Negative Breast Cancer", "TNBC", "HER2+ Breast Cancer", "Non-Small Cell Lung Cancer", "ER/PR Positive Breast Cancer", "HER2- Breast Cancer", "HER2-positive Breast Cancer", "HER2-negative Breast Cancer", "ER/PR(+), Her2(-) Breast Cancer" ], "interventions": [ { "name": "rezatapopt", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PMV Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 300, "start_date": "2020-10-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-06-25T16:10:13.912Z", "location_count": 32, "location_summary": "Irvine, California • La Jolla, California • Los Angeles, California + 25 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04585750" }, { "nct_id": "NCT01037790", "title": "Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Solid Tumor", "Adenocarcinoma of the Colon", "Adenocarcinoma of the Rectum", "Adult Central Nervous System Germ Cell Tumor", "Adult Teratoma", "Benign Teratoma", "Estrogen Receptor-negative Breast Cancer", "Estrogen Receptor-positive Breast Cancer", "Familial Testicular Germ Cell Tumor", "HER2-negative Breast Cancer", "HER2-positive Breast Cancer", "Male Breast Cancer", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Monodermal and Highly Specialized Teratoma", "Progesterone Receptor-negative Breast Cancer", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Recurrent Colon Cancer", "Recurrent Extragonadal Germ Cell Tumor", "Recurrent Extragonadal Non-seminomatous Germ Cell Tumor", "Recurrent Extragonadal Seminoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Melanoma", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Rectal Cancer", "Stage III Extragonadal Non-seminomatous Germ Cell Tumor", "Stage III Extragonadal Seminoma", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Ovarian Germ Cell Tumor", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Extragonadal Non-seminomatous Germ Cell Tumor", "Stage IV Extragonadal Seminoma", "Stage IV Melanoma", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Rectal Cancer", "Testicular Immature Teratoma", "Testicular Mature Teratoma" ], "interventions": [ { "name": "PD-0332991", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 304, "start_date": "2009-10", "completion_date": "2019-10", "has_results": true, "last_update_posted_date": "2021-03-11", "last_synced_at": "2026-06-25T16:10:13.912Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01037790" } ] }